Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2026-09-17 16:28:41 ET · period of report 2026-09-15 · accession 0001859453-26-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 16:28 | 2026-09-15 | VERA | Fordyce Marshall | Pres AND CEO, Dir | M - OptEx | $2.90 | +18.5K | 253.7K | +8% | +$53.6K |
| DT | 2026-09-17 16:28 | 2026-09-15 | VERA | Fordyce Marshall | Pres AND CEO, Dir | S - Sale+OE | $37.00 | -18.5K | 235.2K | -7% | -$684.5K |
| DT | 2026-09-17 16:28 | 2026-09-15 | VERA | Fordyce Marshall | Pres AND CEO, Dir | M - OptEx | $0.00 | -18.5K | 488.8K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-09-15 | M | A | 18,500 | $2.90 | 253,744 | D | — | — | |
| 2 | Common | Class A Common Stock | 2026-09-15 | S | D | 18,500 | $37.00 | 235,244 | D | — | — | (F1) The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-09-15 | M | D | 18,500 | $0.00 | 488,801 | D | $2.90 · — to 2030-12-15 | 18,500 Class A Common Stock | (F2) 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter. |